Big biotech companies have flushed $100 billion in stock buybacks down the toilet

When it comes to the more than $100 billion that big biotech companies have spent in recent years, Leerink analyst Geoffrey Porges might well sing back: Absolutely nothing. , among others, have actually produced a negative rate of return on their stock buybacks, though they were also able to influence earnings-per-share growth in the process.

from Biotech News